• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.

作者信息

Cellerino Maria, Bonavita Simona, Ferrero Margherita, Inglese Matilde, Boffa Giacomo

机构信息

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.

Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.

出版信息

J Neurol Sci. 2020 Nov 15;418:117156. doi: 10.1016/j.jns.2020.117156. Epub 2020 Sep 30.

DOI:10.1016/j.jns.2020.117156
PMID:33010653
Abstract
摘要

相似文献

1
Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.停用芬戈莫德后接受克拉屈滨治疗的多发性硬化症患者的严重疾病活动。
J Neurol Sci. 2020 Nov 15;418:117156. doi: 10.1016/j.jns.2020.117156. Epub 2020 Sep 30.
2
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.在葡萄牙，克拉屈滨片与芬戈莫德治疗高度活跃复发型多发性硬化症的成本效益比较。
J Med Econ. 2020 May;23(5):484-491. doi: 10.1080/13696998.2020.1717499. Epub 2020 Feb 10.
3
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.多发性硬化症患者换用克拉屈滨或利妥昔单抗后出现芬戈莫德反弹风险。
Mult Scler Relat Disord. 2022 Jun;62:103812. doi: 10.1016/j.msard.2022.103812. Epub 2022 Apr 17.
4
Severe fingolimod rebound syndrome after switching to cladribine treatment.切换至克拉屈滨治疗后出现严重芬戈莫德反弹综合征。
Mult Scler Relat Disord. 2020 May;40:101938. doi: 10.1016/j.msard.2020.101938. Epub 2020 Jan 16.
5
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.CLARION 研究设计和最新进展：一项长期、基于登记的研究，评估新开始用克拉屈滨片治疗的复发性多发性硬化症患者的特殊关注不良事件。
Curr Med Res Opin. 2022 Jul;38(7):1167-1176. doi: 10.1080/03007995.2022.2059977. Epub 2022 Apr 28.
6
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.芬兰接受克拉屈滨片治疗的多发性硬化症患者：一项全国性注册研究。
Mult Scler Relat Disord. 2022 May;61:103755. doi: 10.1016/j.msard.2022.103755. Epub 2022 Mar 19.
7
Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.用芬戈莫德治疗的复发缓解型多发性硬化症患者发生默克尔细胞癌。
J Neurol Sci. 2017 Oct 15;381:296-297. doi: 10.1016/j.jns.2017.09.003. Epub 2017 Sep 5.
8
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.西班牙高疾病活动度复发型多发性硬化症的克拉屈滨片和芬戈莫德治疗的成本效益分析。
Expert Rev Pharmacoecon Outcomes Res. 2020 Jun;20(3):295-303. doi: 10.1080/14737167.2019.1635014. Epub 2019 Jul 25.
9
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.多发性硬化症治疗靶点的识别与新进展——聚焦于克拉屈滨
Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627.
10
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.高活性复发型多发性硬化症治疗的成本评估模型。
Adv Ther. 2020 Feb;37(2):800-818. doi: 10.1007/s12325-019-01186-z. Epub 2019 Dec 23.

引用本文的文献

1
Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.多发性硬化症（MS）疾病修饰疗法（DMT）的知识图谱：一项文献计量学分析。
Heliyon. 2024 May 31;10(11):e31744. doi: 10.1016/j.heliyon.2024.e31744. eCollection 2024 Jun 15.
2
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.先前使用芬戈莫德对多发性硬化症患者接受利妥昔单抗/奥瑞珠单抗的早期和晚期反应的影响。
Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200231. doi: 10.1212/NXI.0000000000200231. Epub 2024 Apr 16.
3
Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study).
真实世界中克拉屈滨治疗多发性硬化症的疗效：西西里岛多中心经验（Rewind 研究）。
Curr Neuropharmacol. 2024;22(7):1271-1283. doi: 10.2174/1570159X21666230322140711.
4
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.神经科最新进展：对接受芬戈莫德治疗抵抗的多发性硬化患者进行治疗升级——后续使用高活性药物的潜力和风险。
J Neurol. 2022 May;269(5):2806-2818. doi: 10.1007/s00415-021-10956-1. Epub 2022 Jan 9.
5
Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report.多发性硬化症序贯免疫重建疗法的机遇与障碍：病例报告
Front Neurol. 2021 Dec 8;12:664596. doi: 10.3389/fneur.2021.664596. eCollection 2021.
6
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.从芬戈莫德转换为细胞耗竭剂时多发性硬化症复发的风险：冲洗持续时间的作用。
J Neurol. 2022 Mar;269(3):1463-1469. doi: 10.1007/s00415-021-10708-1. Epub 2021 Jul 22.